AtaiBeckley Inc(ATAI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.19 | Insider Own | 18.53% | Shs Outstand | 369.2M | Perf Week | - |
| Market Cap | 2.73B | Forward P/E | - | EPS next Y | -2.14% | Insider Trans | -0.34% | Shs Float | 302.2M | Perf Month | -0.54% |
| Enterprise Value | 2.50B | PEG | - | EPS next Q | -0.15 | Inst Own | 35.7% | Short Float | 6.35% | Perf Quarter | 38.94% |
| Income | -0.67B | P/S | 609.82 | EPS this Y | 81.27% | Inst Trans | 11.11% | Short Ratio | 1.34 | Perf Half Y | 107.63% |
| Sales | 0.00B | P/B | 15.39 | EPS next 5Y | 43.67% | ROA | - | Short Interest | 19.20M | Perf YTD | 79.71% |
| Book/sh | 0.48 | P/C | 12.07 | EPS past 3/5Y | -43.86% 36.94% | ROE | - | 52W High | -1.34% ($7.45) | Perf Year | 55.72% |
| Cash/sh | 0.61 | P/FCF | - | Sales past 3/5Y | 159.87% - | ROIC | -375.52% | 52W Low | 125.11% ($3.27) | Perf 3Y | 413.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -172% | Gross Margin | - | Volatility(W/M) | 1.37% 0.99% | Perf 5Y | -55.35% |
| Dividend TTM | - | EV/Sales | 559.74 | Sales Y/Y TTM | - | Oper. Margin | -3274.31% | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.58 | EPS Q/Q | 36.07% | Profit Margin | -14938.36% | RSI (14) | 61.81 | Recom | 2.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.58 | Sales Q/Q | 137% | SMA20 | 0.18% ($7.34) | Beta | 1.54 | Target Price | $7.88 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/08/12 | SMA50 | 7.32% ($6.85) | Rel Volume | 0 | Prev Close | $7.35 |
| Employees | 117 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -1.41% 98.88% | SMA200 | 55.76% ($4.72) | Avg Volume(3M) | 14.36M | Price | $7.35 |
| IPO | 2021/6/18 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
🧠 ATAI Life Sciences (ATAI) is a US clinical-stage biotech developing novel drugs based on psychedelics (hallucinogens). It holds multiple clinical pipelines targeting central nervous system disorders such as treatment-resistant depression and anxiety disorders, and was born from the merger of atai Life Sciences and Beckley Psytech. It is regarded as a representative stock aiming to drive a paradigm shift in mental health treatment.
Over the past 1 year, on the higher side
1% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
ATAI has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +81.3% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $60,982. Peers typically go for $1,648.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -55.4%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 35.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #77 of 595 in the industry
Based on market cap of $3B.
FAQ
What kind of company is ATAI?
ATAI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ATAI?
The market cap of ATAI is approximately $2.7B, ranking 1,842 within its sector.
What is the 52-week high and low for ATAI?
ATAI has recorded a 52-week high of $7.45 and a low of $3.27.
